Drug Trial Radar · NCT03525574
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
Last checked: Nov 19, 2026Latest source record: Sep 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
507
Actual
Start
Oct 9, 2018
Primary completion
Jan 9, 2023
Study completion Jan 9, 2023
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- May 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study evaluates the long-term safety and tolerability of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation
Conditions
- Cystic Fibrosis
Interventions
ELX/TEZ/IVADrug
Fixed-dose combination (FDC) tablet for oral administration.
IVADrug
Tablet for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Period: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to Week 196
Locations
110 sites in 13 countries. Site status is shown where the registry gives one.
Banner University of Arizona Medical Center
Tucson, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Miller Children's Hospital / Long Beach Memorial
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Valley Children's Hospital
Madera, California
Kaiser Permanente
Oakland, California
University of California Davis Medical Center
Sacramento, California
UCSF Gateway Medical Center
San Francisco, California
National Jewish Health
Denver, Colorado
University of Florida, Shands Hospital
Gainesville, Florida
Joe DiMaggio Cystic Fibrosis & Pulmonary Center
Hollywood, Florida
Nemours Children's Specialty Care
Jacksonville, Florida
Central Florida Pulmonary Group, PA
Orlando, Florida
Nemours Children's Hospital
Orlando, Florida
Tampa General Hospital Cardiac and Lung Transplant Clinic
Tampa, Florida
Children's Specialty Services at North Druid Hills
Atlanta, Georgia
Augusta University
Augusta, Georgia
Ann & Robert Lurie Children's Hospital of Chicago
Chicago, Illinois
Northwestern Memorial Hospital
Chicago, Illinois
Cystic Fibrosis Center, Children's Hospital of Illinois at OSF Saint Francis Medical Center
Peoria, Illinois
The University of Kansas Medical Center
Kansas City, Kansas
Tulane Medical Center
New Orleans, Louisiana
Maine Medical Partners
Portland, Maine
Massachusetts General Hospital Cystic Fibrosis Center Clinical Research Center
Boston, Massachusetts
Harper University Hospital
Detroit, Michigan
Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota
Minneapolis, Minnesota
Billings Clinic Hospital
Billings, Montana
Nebraska Medical Center
Omaha, Nebraska
Morristown Medical Center
Morristown, New Jersey
UNM Clinical and Translational Science Center
Albuquerque, New Mexico
The Cystic Fibrosis Center, Mount Sinai Beth Israel
New York, New York
New York Medical College
Valhalla, New York
UNC Marsico Clinical Research Center
Chapel Hill, North Carolina
Akron Children's Hospital
Akron, Ohio
UC Health Holmes
Cincinnati, Ohio
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center
Cleveland, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Dayton Children's Hospital
Dayton, Ohio
ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center
Toledo, Ohio
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.